Gilead Sciences, Inc [GILD] stock is trading at $117.86, up 2.26%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GILD shares have gain 4.51% over the last week, with a monthly amount drifted -1.80%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Gilead Sciences, Inc [NASDAQ: GILD] stock has seen the most recent analyst activity on August 19, 2025, when Daiwa Securities upgraded its rating to a Outperform but kept the price target unchanged to $128 for it. Previously, Truist upgraded its rating to Buy on August 08, 2025, and kept the price target unchanged to $127. On July 25, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $133 on the stock. Oppenheimer reiterated its recommendation of a Outperform and raised its price target to $132 on March 04, 2025. Deutsche Bank upgraded its rating to Buy for this stock on February 18, 2025, but kept the price target unchanged to $120. In a note dated February 13, 2025, DZ Bank upgraded an Buy rating on this stock but restated the target price of $108.
Gilead Sciences, Inc [GILD] stock has fluctuated between $79.64 and $121.83 over the past year. Currently, Wall Street analysts expect the stock to reach $125 within the next 12 months. Gilead Sciences, Inc [NASDAQ: GILD] shares were valued at $117.86 at the most recent close of the market. An investor can expect a potential return of 6.06% based on the average GILD price forecast.
Analyzing the GILD fundamentals
Gilead Sciences, Inc [NASDAQ:GILD] reported sales of 28.80B for the trailing twelve months, which represents a growth of 1.64%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.33 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 116.02 points at the first support level, and at 114.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.91, and for the 2nd resistance point, it is at 119.95.
Ratios To Look Out For
For context, Gilead Sciences, Inc’s Current Ratio is 1.32. In addition, the Quick Ratio stands at 1.15 and the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 5.08, the price to book ratio is 7.44 and price to earnings (TTM) ratio is 23.44.
Transactions by insiders
Recent insider trading involved O’Day Daniel Patrick, Chairman & CEO, that happened on Aug 28 ’25 when 10000.0 shares were sold. Officer, DANIEL O’DAY completed a deal on Aug 28 ’25 to buy 10000.0 shares. Meanwhile, Chief Commercial Officer Mercier Johanna sold 28000.0 shares on Aug 15 ’25.
